Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&display=swap\" rel=\"stylesheet\">\n<style>\n#npk05 *,#npk05 *::before,#npk05 *::after{box-sizing:border-box;margin:0;padding:0}\n#npk05{\n --ob:#1A5F7A;--ob-light:#236E8C;--ob-pale:#E6F3F7;--ob-dark:#114455;\n --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n --ink:#0F2A35;--ink-mid:#2A4D5A;--ink-soft:#5A7D8A;\n --line:#B8D8E3;--cream:#F2F8FA;--warm:#F8FCFD;\n font-family:'Source Serif 4',Georgia,serif;\n font-size:16px;color:var(--ink);background:var(--cream);\n line-height:1.7;padding:0 0 64px;\n}\n#npk05 .mr-header{background:linear-gradient(135deg,var(--ob-dark) 0%,var(--ob) 60%,var(--ob-light) 100%);color:#E4F4F9;padding:36px 24px 30px;text-align:center;position:relative;overflow:hidden;}\n#npk05 .mr-header::before{content:'';position:absolute;inset:0;background:repeating-linear-gradient(45deg,transparent,transparent 18px,rgba(255,255,255,0.03) 18px,rgba(255,255,255,0.03) 19px);}\n#npk05 .mr-eyebrow{font-size:0.66rem;letter-spacing:0.22em;text-transform:uppercase;font-weight:700;opacity:0.6;margin-bottom:10px;position:relative;}\n#npk05 .mr-series-tag{display:inline-block;background:rgba(255,255,255,0.12);border:1px solid rgba(255,255,255,0.2);border-radius:4px;padding:2px 10px;font-size:0.64rem;letter-spacing:0.14em;text-transform:uppercase;font-weight:700;margin-bottom:14px;position:relative;}\n#npk05 .mr-title{font-family:'Playfair Display',serif;font-size:1.8rem;font-weight:700;line-height:1.2;margin-bottom:6px;position:relative;}\n#npk05 .mr-title em{font-style:italic;font-weight:400;opacity:0.85}\n#npk05 .mr-subtitle{font-size:0.82rem;opacity:0.65;margin-top:8px;font-style:italic;position:relative;}\n#npk05 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap;position:relative;}\n#npk05 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.72rem;}\n#npk05 .mr-sentinel{height:1px}\n#npk05 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(15,42,53,0.1);padding:9px 16px;display:none;}\n#npk05 .mr-progress.visible{display:block}\n#npk05 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#npk05 .mr-pips{display:flex;align-items:center;justify-content:center}\n#npk05 .mr-pip-wrap{display:flex;align-items:center}\n#npk05 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#npk05 .mr-pip-line.done{background:var(--ob)}\n#npk05 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0;}\n#npk05 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk05 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk05 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#npk05 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ob);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 8px rgba(15,42,53,0.07);}\n#npk05 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#npk05 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ob);opacity:0.14;line-height:1;margin-top:-2px;flex-shrink:0;}\n#npk05 .mr-meta{flex:1}\n#npk05 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob);opacity:0.8;margin-bottom:5px;}\n#npk05 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#npk05 .mr-stem strong{font-weight:600}\n#npk05 .mr-stem em{font-style:italic}\n#npk05 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#npk05 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#npk05 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent;}\n#npk05 .mr-opt:hover{border-color:var(--ob);background:var(--ob-pale)}\n#npk05 .mr-opt.locked{cursor:default}\n#npk05 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#npk05 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#npk05 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#npk05 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#npk05 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#npk05 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#npk05 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#npk05 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s;}\n#npk05 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk05 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk05 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#npk05 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#npk05 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#npk05 .mr-exp{display:none;border-top:1px solid #9CCFDF;background:linear-gradient(180deg,#D4EEF7 0%,#EAF5FA 100%);padding:13px 20px 15px;}\n#npk05 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob-dark);margin-bottom:6px;}\n#npk05 .mr-exp-text{font-size:0.86rem;color:#0F2A35;line-height:1.7}\n#npk05 .mr-exp-text strong{font-weight:600}\n#npk05 .mr-exp-text em{font-style:italic}\n#npk05 .mr-exp-text .calc{display:block;background:rgba(26,95,122,0.08);border-left:3px solid var(--ob);border-radius:0 4px 4px 0;padding:6px 10px;margin:8px 0;font-family:Georgia,serif;font-size:0.84rem;color:var(--ob-dark);}\n#npk05 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#npk05 .mr-btn{background:var(--ob);color:#E4F4F9;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 10px rgba(26,95,122,0.32);}\n#npk05 .mr-btn:hover{background:var(--ob-dark)}\n#npk05 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ob);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(15,42,53,0.08);overflow:hidden;}\n#npk05 .mr-score-in{padding:28px 24px;text-align:center}\n#npk05 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600;}\n#npk05 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ob) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative;}\n#npk05 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm);}\n#npk05 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#npk05 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ob)}\n#npk05 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#npk05 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#npk05 .mr-score-net{font-size:0.9rem;color:var(--ob);font-weight:600;margin-bottom:4px}\n#npk05 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#npk05 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#npk05 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#npk05 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#npk05 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#npk05 .mr-band-s{background:var(--ob-pale);color:var(--ob)}\n#npk05 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ob);color:var(--ob);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer;}\n#npk05 .mr-retry:hover{background:var(--ob);color:#E4F4F9}\n@media(max-width:480px){\n #npk05 .mr-title{font-size:1.4rem}\n #npk05 .mr-num{font-size:1.7rem}\n #npk05 .mr-stem{font-size:0.9rem}\n #npk05 .mr-opt-text{font-size:0.86rem}\n}\n<\/style>\n\n<div id=\"npk05\">\n\n <div class=\"mr-header\">\n <div class=\"mr-series-tag\">Numerical Series · Pharmacokinetics<\/div>\n <div class=\"mr-eyebrow\">Morning Rounds · Round 05 of 07<\/div>\n <div class=\"mr-title\">Therapeutic Index,<br><em>ED50 & LD50<\/em><\/div>\n <div class=\"mr-subtitle\">Five questions · Safety margins, dose-response curves & the drugs that live on the edge<\/div>\n <div class=\"mr-chips\">\n <span class=\"mr-chip\">5 Questions<\/span>\n <span class=\"mr-chip\">+4 \/ −1 scoring<\/span>\n <span class=\"mr-chip\">Options reshuffled<\/span>\n <\/div>\n <\/div>\n\n <div class=\"mr-sentinel\" id=\"npk05-sentinel\"><\/div>\n\n <div class=\"mr-progress\" id=\"npk05-progress\">\n <div class=\"mr-prog-inner\">\n <div class=\"mr-pips\" id=\"npk05-pips\"><\/div>\n <\/div>\n <\/div>\n\n <div class=\"mr-body\">\n <div id=\"npk05-cases\"><\/div>\n <div class=\"mr-submit-wrap\">\n <button class=\"mr-btn\" id=\"npk05-submit\">Submit for Debrief<\/button>\n <\/div>\n <div class=\"mr-score\" id=\"npk05-score\">\n <div class=\"mr-score-in\">\n <div class=\"mr-score-ey\">Round Complete<\/div>\n <div class=\"mr-ring\" id=\"npk05-ring\">\n <div class=\"mr-ring-in\">\n <span class=\"mr-ring-pct\" id=\"npk05-pct\">0%<\/span>\n <span class=\"mr-ring-sub\">net<\/span>\n <\/div>\n <\/div>\n <div class=\"mr-score-title\">Your Debrief<\/div>\n <div class=\"mr-score-net\" id=\"npk05-net\"><\/div>\n <div class=\"mr-verdict\" id=\"npk05-verdict\"><\/div>\n <div class=\"mr-bands\">\n <span class=\"mr-band mr-band-c\" id=\"npk05-ct-c\"><\/span>\n <span class=\"mr-band mr-band-w\" id=\"npk05-ct-w\"><\/span>\n <span class=\"mr-band mr-band-s\" id=\"npk05-ct-s\"><\/span>\n <\/div>\n <button class=\"mr-retry\" id=\"npk05-retry\">↻ New Round<\/button>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n<script>\n(function () {\n 'use strict';\n\n var NS = 'npk05';\n var TOTAL = 5;\n var MAX = 20;\n var LTRS = ['A','B','C','D'];\n\n var QS = [\n\n {\n id: 1,\n tag: 'Therapeutic Index — Formula & Calculation',\n stem: 'In an animal study, a drug produces the desired effect in 50% of animals at a dose of <strong>20 mg\/kg<\/strong>, and causes death in 50% of animals at a dose of <strong>200 mg\/kg<\/strong>. What is the <strong>therapeutic index<\/strong> of this drug, and how should it be interpreted?',\n correct: 'TI = 10; the drug has a relatively wide safety margin with a tenfold difference between the effective and lethal doses',\n opts: [\n 'TI = 10; the drug has a relatively wide safety margin with a tenfold difference between the effective and lethal doses',\n 'TI = 0.1; the drug is dangerous because the lethal dose is only a fraction of the effective dose',\n 'TI = 10; the drug has a narrow safety margin and requires therapeutic drug monitoring',\n 'TI = 180; calculated as the difference between LD50 and ED50, representing the absolute safe dose range'\n ],\n exp: 'The formula \u2014 and the direction of division matter:<span class=\"calc\">Therapeutic Index (TI) = LD50 ÷ ED50<br>= 200 mg\/kg ÷ 20 mg\/kg = <strong>10<\/strong><\/span>Interpretation: a TI of 10 means the lethal dose is <strong>10 times<\/strong> the effective dose. This is actually a <em>reasonable<\/em> safety margin \u2014 not narrow. Trap C gives the right number but the wrong interpretation. Trap B inverts the formula (ED50 ÷ LD50), giving 0.1. Trap D subtracts instead of divides \u2014 a common arithmetic error. <br><br>Reference anchors for TI:<br>• <strong>TI > 10<\/strong> \u2192 relatively safe (e.g. penicillin, TI > 100)<br>• <strong>TI < 2<\/strong> \u2192 narrow therapeutic index; requires monitoring<br>• Classic NTI drugs: <strong>digoxin, lithium, phenytoin, warfarin, theophylline, aminoglycosides<\/strong>'\n },\n\n {\n id: 2,\n tag: 'Therapeutic Index — Narrow vs Wide, Clinical Consequences',\n stem: 'Drug A has a therapeutic index of <strong>1.5<\/strong>. Drug B has a therapeutic index of <strong>100<\/strong>. A patient on Drug A develops mild renal impairment causing a <strong>30% reduction in drug clearance<\/strong>. Which statement best describes the clinical consequence?',\n correct: 'Drug A becomes immediately dangerous; a 30% rise in plasma concentration in a drug with TI of 1.5 is likely to push the patient into the toxic range',\n opts: [\n 'Drug A becomes immediately dangerous; a 30% rise in plasma concentration in a drug with TI of 1.5 is likely to push the patient into the toxic range',\n 'Drug B is more dangerous because it has a higher absolute plasma concentration at therapeutic doses',\n 'Both drugs are equally affected; a 30% reduction in clearance raises plasma concentration by 30% regardless of TI',\n 'Drug A is safer because its low TI means the body tolerates a wider range of plasma concentrations before toxic effects appear'\n ],\n exp: 'Reduced clearance \u2192 reduced elimination \u2192 drug accumulates \u2192 plasma concentration rises ~30%.<br><br>Now apply TI:<span class=\"calc\">Drug A: TI = 1.5<br>Toxic dose = only 1.5\u00d7 the effective dose<br>A 30% rise in concentration crosses into toxic territory immediately.<br><br>Drug B: TI = 100<br>Toxic dose = 100\u00d7 the effective dose<br>A 30% rise is clinically trivial — still far from toxicity.<\/span>This is the <em>clinical meaning<\/em> of TI: it defines how much room you have. Drug A with TI 1.5 has almost none. Trap C is arithmetically true but clinically meaningless without TI context. Trap D inverts the logic completely — a low TI means <strong>less<\/strong> tolerance, not more. NTI drugs (digoxin, lithium, warfarin) need monitoring precisely because small clearance changes tip patients into toxicity.'\n },\n\n {\n id: 3,\n tag: 'ED50 — Dose-Response Curve Reading',\n stem: 'Two drugs, X and Y, both treat the same condition. Drug X produces 50% of maximal effect at <strong>5 mg<\/strong>. Drug Y produces 50% of maximal effect at <strong>50 mg<\/strong>. The maximal effect of both drugs is identical. Which statement is correct?',\n correct: 'Drug X is more potent than Drug Y; it achieves the same submaximal effect at a tenfold lower dose, though potency says nothing about the maximum effect either drug can produce',\n opts: [\n 'Drug X is more potent than Drug Y; it achieves the same submaximal effect at a tenfold lower dose, though potency says nothing about the maximum effect either drug can produce',\n 'Drug X is more efficacious than Drug Y because it requires a lower dose to produce its effect',\n 'Drug Y is safer than Drug X because its higher ED50 means toxic effects occur at proportionally higher doses',\n 'Drug X and Drug Y have identical clinical utility since their maximal effects are the same; ED50 is irrelevant when efficacy is equal'\n ],\n exp: '<strong>Potency vs Efficacy<\/strong> \u2014 the distinction examiners love:<br><br>• <strong>Potency<\/strong>: the dose required to produce a given effect. Lower ED50 = more potent. Drug X (ED50 = 5 mg) is <strong>10\u00d7 more potent<\/strong> than Drug Y (ED50 = 50 mg).<br>• <strong>Efficacy<\/strong>: the <em>maximum<\/em> effect a drug can produce. Both drugs have identical maximum effect \u2192 <strong>equal efficacy<\/strong>.<span class=\"calc\">Potency ratio = ED50(Y) ÷ ED50(X) = 50 ÷ 5 = <strong>10<\/strong><br>Drug X is 10\u00d7 more potent.<\/span>Trap B conflates potency with efficacy \u2014 a lower dose requirement does not mean a greater maximum effect. Trap C is wrong: ED50 says nothing about the toxic dose (that is LD50 or TD50). Trap D is wrong: potency matters clinically for dosing convenience and side-effect profile even when maximal efficacy is equal. Morphine and codeine have the same ceiling, but morphine\\'s higher potency makes it the choice for severe pain.'\n },\n\n {\n id: 4,\n tag: 'Certain Safety Factor — TD50 vs LD50',\n stem: 'In human pharmacology, the <strong>Certain Safety Factor (CSF)<\/strong> is preferred over the classic therapeutic index for assessing drug safety. Given: ED99 = <strong>40 mg\/kg<\/strong> and TD1 = <strong>80 mg\/kg<\/strong>. What is the CSF, and what does it tell you?',\n correct: 'CSF = 2; this means the dose causing toxicity in the most sensitive 1% of the population is only twice the dose needed to treat the most resistant 1% of patients \u2014 a dangerously narrow margin',\n opts: [\n 'CSF = 2; this means the dose causing toxicity in the most sensitive 1% of the population is only twice the dose needed to treat the most resistant 1% of patients \u2014 a dangerously narrow margin',\n 'CSF = 2; this is a comfortable safety margin since the toxic dose always exceeds the effective dose in clinical use',\n 'CSF = 0.5; calculated as ED99 ÷ TD1, indicating the effective dose exceeds the toxic dose and the drug should not be used',\n 'CSF = 40; calculated as the absolute difference between TD1 and ED99, representing milligrams of available safety window'\n ],\n exp: 'Formula:<span class=\"calc\">CSF = TD1 ÷ ED99<br>= 80 mg\/kg ÷ 40 mg\/kg = <strong>2<\/strong><\/span>Why CSF is more informative than TI:<br><br>Classic TI uses <strong>median values<\/strong> (LD50\/ED50) \u2014 middle of the population. But populations have outliers. CSF asks a harder question: what happens when you give the dose needed to treat the <em>hardest-to-treat<\/em> patient (ED99) to someone who is the <em>most sensitive to toxicity<\/em> (TD1)?<br><br>A CSF of 2 means these two curves nearly overlap. In a real population, some patients will be harmed while being treated at doses needed to treat others. CSF < 1 means the curves cross \u2014 you cannot treat all patients without harming some. Classic NTI examples: digoxin CSF is close to 1. Trap B mistakes \"CSF >1\" for \"safe\" \u2014 that is only valid when CSF is substantially >1. Trap C inverts the formula.'\n },\n\n {\n id: 5,\n tag: 'TI — Comparing Two Drugs Clinically',\n stem: 'A new sedative (Drug N) and an established sedative (Drug E) are compared in animal studies:<br><br><strong>Drug N:<\/strong> ED50 = 10 mg\/kg | LD50 = 15 mg\/kg<br><strong>Drug E:<\/strong> ED50 = 50 mg\/kg | LD50 = 500 mg\/kg<br><br>Which drug would you prefer for clinical use, and why?',\n correct: 'Drug E; its TI of 10 is far safer than Drug N\\'s TI of 1.5, despite Drug N appearing more potent',\n opts: [\n 'Drug E; its TI of 10 is far safer than Drug N\\'s TI of 1.5, despite Drug N appearing more potent',\n 'Drug N; its lower ED50 means it is more potent and therefore requires smaller, safer doses in clinical practice',\n 'Drug N; since both LD50 values are above the ED50, both drugs are equally safe and the choice should be based on cost',\n 'Drug E; its higher ED50 means patients are less likely to accidentally take an effective dose, reducing the risk of overdose'\n ],\n exp: 'Calculate TI for both:<span class=\"calc\">Drug N: TI = LD50 ÷ ED50 = 15 ÷ 10 = <strong>1.5<\/strong><br>Drug E: TI = LD50 ÷ ED50 = 500 ÷ 50 = <strong>10<\/strong><\/span>Drug N is more <em>potent<\/em> (lower ED50) but dramatically less <em>safe<\/em>. A TI of 1.5 means the lethal dose is only 50% above the effective dose \u2014 an almost nonexistent margin. Any dosing error, pharmacokinetic variability, or drug interaction could prove fatal.<br><br>Drug E with TI = 10 has a tenfold buffer. This is the core lesson of TI: <strong>potency and safety are independent axes<\/strong>. The most potent drug is not the best drug. Botulinum toxin is the most potent substance known \u2014 its ED is vanishingly small, but so is its margin to lethality. Trap B is the classic error of equating potency with safety. Trap D is creative but pharmacologically backwards \u2014 a high ED50 is not a safety feature, it just means you need more drug.'\n }\n\n ];\n\n var answers = {}, answered = 0, shuffled = {}, done = false;\n\n function gid(s) { return document.getElementById(NS + '-' + s); }\n function byId(s) { return document.getElementById(s); }\n\n function shuffleArr(arr) {\n var a = arr.slice(), i, j, t;\n for (i = a.length - 1; i > 0; i--) {\n j = Math.floor(Math.random() * (i + 1));\n t = a[i]; a[i] = a[j]; a[j] = t;\n }\n return a;\n }\n\n function countVal(v) {\n var n = 0, k;\n for (k in answers) { if (answers[k] === v) n++; }\n return n;\n }\n\n function buildPips() {\n var cont = gid('pips'), i, q, wLine, wPip, line, pip;\n cont.innerHTML = '';\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n if (i > 0) {\n wLine = document.createElement('div');\n wLine.className = 'mr-pip-wrap';\n line = document.createElement('div');\n line.className = 'mr-pip-line';\n line.id = NS + '-pl' + q.id;\n wLine.appendChild(line);\n cont.appendChild(wLine);\n }\n wPip = document.createElement('div');\n wPip.className = 'mr-pip-wrap';\n pip = document.createElement('div');\n pip.className = 'mr-pip';\n pip.id = NS + '-pip' + q.id;\n pip.textContent = String(q.id);\n wPip.appendChild(pip);\n cont.appendChild(wPip);\n }\n }\n\n function build() {\n var cont, i, q, opts, card, top, numDiv, meta, tag, stem,\n rule, optsDiv, expDiv, lbl, txt, j, optEl, ltrSpan, txtSpan;\n\n cont = gid('cases');\n cont.innerHTML = '';\n answers = {}; answered = 0; shuffled = {}; done = false;\n gid('score').style.display = 'none';\n buildPips();\n\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n opts = shuffleArr(q.opts);\n shuffled[q.id] = opts;\n\n card = document.createElement('div');\n card.className = 'mr-case';\n\n top = document.createElement('div');\n top.className = 'mr-case-top';\n\n numDiv = document.createElement('div');\n numDiv.className = 'mr-num';\n numDiv.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n\n meta = document.createElement('div');\n meta.className = 'mr-meta';\n\n tag = document.createElement('div');\n tag.className = 'mr-tag';\n tag.innerHTML = q.tag;\n\n stem = document.createElement('div');\n stem.className = 'mr-stem';\n stem.innerHTML = q.stem;\n\n meta.appendChild(tag);\n meta.appendChild(stem);\n top.appendChild(numDiv);\n top.appendChild(meta);\n card.appendChild(top);\n\n rule = document.createElement('div');\n rule.className = 'mr-rule';\n card.appendChild(rule);\n\n optsDiv = document.createElement('div');\n optsDiv.className = 'mr-opts';\n\n for (j = 0; j < opts.length; j++) {\n optEl = document.createElement('div');\n optEl.className = 'mr-opt';\n optEl.id = NS + '-o' + q.id + '-' + j;\n optEl.setAttribute('role', 'button');\n optEl.setAttribute('tabindex', '0');\n\n ltrSpan = document.createElement('span');\n ltrSpan.className = 'mr-ltr';\n ltrSpan.textContent = LTRS[j];\n\n txtSpan = document.createElement('span');\n txtSpan.className = 'mr-opt-text';\n txtSpan.innerHTML = opts[j];\n\n optEl.appendChild(ltrSpan);\n optEl.appendChild(txtSpan);\n optsDiv.appendChild(optEl);\n\n (function (qid, oi) {\n optEl.addEventListener('click', function () { pick(qid, oi); });\n }(q.id, j));\n }\n card.appendChild(optsDiv);\n\n expDiv = document.createElement('div');\n expDiv.className = 'mr-exp';\n expDiv.id = NS + '-exp' + q.id;\n\n lbl = document.createElement('div');\n lbl.className = 'mr-exp-lbl';\n lbl.textContent = 'Debrief';\n\n txt = document.createElement('div');\n txt.className = 'mr-exp-text';\n txt.innerHTML = q.exp;\n\n expDiv.appendChild(lbl);\n expDiv.appendChild(txt);\n card.appendChild(expDiv);\n cont.appendChild(card);\n }\n }\n\n function pick(qid, oi) {\n var q, opts, i, el, correct;\n if (answers[qid] !== undefined || done) return;\n\n q = null;\n for (i = 0; i < QS.length; i++) {\n if (QS[i].id === qid) { q = QS[i]; break; }\n }\n if (!q) return;\n\n opts = shuffled[qid];\n correct = (opts[oi] === q.correct);\n answers[qid] = correct ? 'c' : 'w';\n answered++;\n\n for (i = 0; i < opts.length; i++) {\n el = byId(NS + '-o' + qid + '-' + i);\n if (opts[i] === q.correct) {\n el.className = 'mr-opt correct locked';\n } else if (i === oi) {\n el.className = 'mr-opt wrong locked';\n } else {\n el.className = 'mr-opt dimmed locked';\n }\n }\n\n byId(NS + '-exp' + qid).style.display = 'block';\n byId(NS + '-pip' + qid).className = 'mr-pip ' + (correct ? 'correct' : 'wrong');\n\n if (qid > 1) {\n var pl = byId(NS + '-pl' + qid);\n if (pl) { pl.className = 'mr-pip-line done'; }\n }\n }\n\n function showScore() {\n var c, w, s, net, pct, disp, verdicts, vi, sc;\n if (done) return;\n done = true;\n\n c = countVal('c');\n w = countVal('w');\n s = TOTAL - answered;\n net = (c * 4) - w;\n pct = Math.max(0, Math.round((net \/ MAX) * 100));\n disp = Math.min(100, Math.max(0, pct));\n\n gid('ring').style.background =\n 'conic-gradient(#1A5F7A ' + disp + '%, #B8D8E3 0%)';\n\n gid('pct').textContent = pct + '%';\n gid('net').textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n\n verdicts = [\n [5, 'Perfect. TI formula, CSF, potency vs efficacy \\u2014 all sharp. These are free marks in the exam.'],\n [4, 'Strong round. One concept to consolidate \\u2014 check the debrief and move on.'],\n [3, 'Good base. The CSF question and potency\\u2013efficacy distinction are where the gaps are \\u2014 re-read those two debriefs.'],\n [2, 'The TI formula is the foundation. Own it cold: LD50 \\u00f7 ED50, higher is safer. Everything else builds from there.'],\n [0, 'Start with Q1 and Q5 \\u2014 both are pure calculation. Once the formula is locked in, the conceptual questions become readable.']\n ];\n gid('verdict').textContent = verdicts[4][1];\n for (vi = 0; vi < verdicts.length; vi++) {\n if (c >= verdicts[vi][0]) {\n gid('verdict').innerHTML = verdicts[vi][1];\n break;\n }\n }\n\n gid('ct-c').textContent = '\\u2705 ' + c + ' Correct';\n gid('ct-w').textContent = '\\u274C ' + w + ' Wrong';\n gid('ct-s').textContent = '\\u23ED ' + s + ' Skipped';\n\n sc = gid('score');\n sc.style.display = 'block';\n sc.scrollIntoView({ behavior: 'smooth', block: 'center' });\n }\n\n function tryInit() {\n var sentinel = document.getElementById(NS + '-sentinel');\n var submit = document.getElementById(NS + '-submit');\n var retry = document.getElementById(NS + '-retry');\n if (!sentinel || !submit || !retry) {\n setTimeout(tryInit, 80);\n return;\n }\n submit.addEventListener('click', showScore);\n retry.addEventListener('click', function () {\n build();\n window.scrollTo(0, 0);\n });\n var bar = document.getElementById(NS + '-progress');\n if (bar && window.IntersectionObserver) {\n new IntersectionObserver(function (entries) {\n bar.className = entries[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n }, { threshold: 0 }).observe(sentinel);\n }\n build();\n }\n\n tryInit();\n\n}());\n<\/script>\n\n<\/html>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05 Numerical Series · Pharmacokinetics Morning Rounds · Round 05 of 07 Therapeutic Index,ED50 & LD50 Five questions · Safety margins, dose-response curves & the drugs that live on the edge 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻… <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,79],"tags":[83],"class_list":["post-37349","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-pharmacology","tag-neet-pg"],"yoast_head":"\n<title>Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05 Numerical Series · Pharmacokinetics Morning Rounds · Round 05 of 07 Therapeutic Index,ED50 & LD50 Five questions · Safety margins, dose-response curves & the drugs that live on the edge 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻… \" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-23T05:01:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-23T05:01:59+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Pharmacokinetics – Therapeutic Index, ED50 & LD50\",\"datePublished\":\"2026-08-23T05:01:14+00:00\",\"dateModified\":\"2026-08-23T05:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\"},\"wordCount\":55,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"keywords\":[\"NEET-PG\"],\"articleSection\":[\"Morning Rounds\",\"Pharmacology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\",\"name\":\"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-08-23T05:01:14+00:00\",\"dateModified\":\"2026-08-23T05:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacokinetics – Therapeutic Index, ED50 & LD50\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n","yoast_head_json":{"title":"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","og_locale":"en_US","og_type":"article","og_title":"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty","og_description":"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05 Numerical Series · Pharmacokinetics Morning Rounds · Round 05 of 07 Therapeutic Index,ED50 & LD50 Five questions · Safety margins, dose-response curves & the drugs that live on the edge 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻… ","og_url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","og_site_name":"atsixty","article_published_time":"2026-08-23T05:01:14+00:00","article_modified_time":"2026-08-23T05:01:59+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Pharmacokinetics – Therapeutic Index, ED50 & LD50","datePublished":"2026-08-23T05:01:14+00:00","dateModified":"2026-08-23T05:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/"},"wordCount":55,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"keywords":["NEET-PG"],"articleSection":["Morning Rounds","Pharmacology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","name":"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-08-23T05:01:14+00:00","dateModified":"2026-08-23T05:01:59+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Pharmacokinetics – Therapeutic Index, ED50 & LD50"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37349"}],"version-history":[{"count":2,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37349\/revisions"}],"predecessor-version":[{"id":37351,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37349\/revisions\/37351"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

{"id":37349,"date":"2026-08-23T10:31:14","date_gmt":"2026-08-23T05:01:14","guid":{"rendered":"https:\/\/atsixty.com\/?p=37349"},"modified":"2026-08-23T10:31:59","modified_gmt":"2026-08-23T05:01:59","slug":"pharmacokinetics-therapeutic-index-ed50-ld50","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","title":{"rendered":"Pharmacokinetics – Therapeutic Index, ED50 & LD50"},"content":{"rendered":"\n\n\n\n\n\n\n\nMorning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&display=swap\" rel=\"stylesheet\">\n<style>\n#npk05 *,#npk05 *::before,#npk05 *::after{box-sizing:border-box;margin:0;padding:0}\n#npk05{\n --ob:#1A5F7A;--ob-light:#236E8C;--ob-pale:#E6F3F7;--ob-dark:#114455;\n --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n --ink:#0F2A35;--ink-mid:#2A4D5A;--ink-soft:#5A7D8A;\n --line:#B8D8E3;--cream:#F2F8FA;--warm:#F8FCFD;\n font-family:'Source Serif 4',Georgia,serif;\n font-size:16px;color:var(--ink);background:var(--cream);\n line-height:1.7;padding:0 0 64px;\n}\n#npk05 .mr-header{background:linear-gradient(135deg,var(--ob-dark) 0%,var(--ob) 60%,var(--ob-light) 100%);color:#E4F4F9;padding:36px 24px 30px;text-align:center;position:relative;overflow:hidden;}\n#npk05 .mr-header::before{content:'';position:absolute;inset:0;background:repeating-linear-gradient(45deg,transparent,transparent 18px,rgba(255,255,255,0.03) 18px,rgba(255,255,255,0.03) 19px);}\n#npk05 .mr-eyebrow{font-size:0.66rem;letter-spacing:0.22em;text-transform:uppercase;font-weight:700;opacity:0.6;margin-bottom:10px;position:relative;}\n#npk05 .mr-series-tag{display:inline-block;background:rgba(255,255,255,0.12);border:1px solid rgba(255,255,255,0.2);border-radius:4px;padding:2px 10px;font-size:0.64rem;letter-spacing:0.14em;text-transform:uppercase;font-weight:700;margin-bottom:14px;position:relative;}\n#npk05 .mr-title{font-family:'Playfair Display',serif;font-size:1.8rem;font-weight:700;line-height:1.2;margin-bottom:6px;position:relative;}\n#npk05 .mr-title em{font-style:italic;font-weight:400;opacity:0.85}\n#npk05 .mr-subtitle{font-size:0.82rem;opacity:0.65;margin-top:8px;font-style:italic;position:relative;}\n#npk05 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap;position:relative;}\n#npk05 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.72rem;}\n#npk05 .mr-sentinel{height:1px}\n#npk05 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(15,42,53,0.1);padding:9px 16px;display:none;}\n#npk05 .mr-progress.visible{display:block}\n#npk05 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#npk05 .mr-pips{display:flex;align-items:center;justify-content:center}\n#npk05 .mr-pip-wrap{display:flex;align-items:center}\n#npk05 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#npk05 .mr-pip-line.done{background:var(--ob)}\n#npk05 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0;}\n#npk05 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk05 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk05 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#npk05 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ob);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 8px rgba(15,42,53,0.07);}\n#npk05 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#npk05 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ob);opacity:0.14;line-height:1;margin-top:-2px;flex-shrink:0;}\n#npk05 .mr-meta{flex:1}\n#npk05 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob);opacity:0.8;margin-bottom:5px;}\n#npk05 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#npk05 .mr-stem strong{font-weight:600}\n#npk05 .mr-stem em{font-style:italic}\n#npk05 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#npk05 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#npk05 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent;}\n#npk05 .mr-opt:hover{border-color:var(--ob);background:var(--ob-pale)}\n#npk05 .mr-opt.locked{cursor:default}\n#npk05 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#npk05 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#npk05 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#npk05 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#npk05 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#npk05 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#npk05 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#npk05 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s;}\n#npk05 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk05 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk05 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#npk05 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#npk05 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#npk05 .mr-exp{display:none;border-top:1px solid #9CCFDF;background:linear-gradient(180deg,#D4EEF7 0%,#EAF5FA 100%);padding:13px 20px 15px;}\n#npk05 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob-dark);margin-bottom:6px;}\n#npk05 .mr-exp-text{font-size:0.86rem;color:#0F2A35;line-height:1.7}\n#npk05 .mr-exp-text strong{font-weight:600}\n#npk05 .mr-exp-text em{font-style:italic}\n#npk05 .mr-exp-text .calc{display:block;background:rgba(26,95,122,0.08);border-left:3px solid var(--ob);border-radius:0 4px 4px 0;padding:6px 10px;margin:8px 0;font-family:Georgia,serif;font-size:0.84rem;color:var(--ob-dark);}\n#npk05 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#npk05 .mr-btn{background:var(--ob);color:#E4F4F9;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 10px rgba(26,95,122,0.32);}\n#npk05 .mr-btn:hover{background:var(--ob-dark)}\n#npk05 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ob);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(15,42,53,0.08);overflow:hidden;}\n#npk05 .mr-score-in{padding:28px 24px;text-align:center}\n#npk05 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600;}\n#npk05 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ob) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative;}\n#npk05 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm);}\n#npk05 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#npk05 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ob)}\n#npk05 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#npk05 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#npk05 .mr-score-net{font-size:0.9rem;color:var(--ob);font-weight:600;margin-bottom:4px}\n#npk05 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#npk05 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#npk05 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#npk05 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#npk05 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#npk05 .mr-band-s{background:var(--ob-pale);color:var(--ob)}\n#npk05 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ob);color:var(--ob);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer;}\n#npk05 .mr-retry:hover{background:var(--ob);color:#E4F4F9}\n@media(max-width:480px){\n #npk05 .mr-title{font-size:1.4rem}\n #npk05 .mr-num{font-size:1.7rem}\n #npk05 .mr-stem{font-size:0.9rem}\n #npk05 .mr-opt-text{font-size:0.86rem}\n}\n<\/style>\n\n<div id=\"npk05\">\n\n <div class=\"mr-header\">\n <div class=\"mr-series-tag\">Numerical Series · Pharmacokinetics<\/div>\n <div class=\"mr-eyebrow\">Morning Rounds · Round 05 of 07<\/div>\n <div class=\"mr-title\">Therapeutic Index,<br><em>ED50 & LD50<\/em><\/div>\n <div class=\"mr-subtitle\">Five questions · Safety margins, dose-response curves & the drugs that live on the edge<\/div>\n <div class=\"mr-chips\">\n <span class=\"mr-chip\">5 Questions<\/span>\n <span class=\"mr-chip\">+4 \/ −1 scoring<\/span>\n <span class=\"mr-chip\">Options reshuffled<\/span>\n <\/div>\n <\/div>\n\n <div class=\"mr-sentinel\" id=\"npk05-sentinel\"><\/div>\n\n <div class=\"mr-progress\" id=\"npk05-progress\">\n <div class=\"mr-prog-inner\">\n <div class=\"mr-pips\" id=\"npk05-pips\"><\/div>\n <\/div>\n <\/div>\n\n <div class=\"mr-body\">\n <div id=\"npk05-cases\"><\/div>\n <div class=\"mr-submit-wrap\">\n <button class=\"mr-btn\" id=\"npk05-submit\">Submit for Debrief<\/button>\n <\/div>\n <div class=\"mr-score\" id=\"npk05-score\">\n <div class=\"mr-score-in\">\n <div class=\"mr-score-ey\">Round Complete<\/div>\n <div class=\"mr-ring\" id=\"npk05-ring\">\n <div class=\"mr-ring-in\">\n <span class=\"mr-ring-pct\" id=\"npk05-pct\">0%<\/span>\n <span class=\"mr-ring-sub\">net<\/span>\n <\/div>\n <\/div>\n <div class=\"mr-score-title\">Your Debrief<\/div>\n <div class=\"mr-score-net\" id=\"npk05-net\"><\/div>\n <div class=\"mr-verdict\" id=\"npk05-verdict\"><\/div>\n <div class=\"mr-bands\">\n <span class=\"mr-band mr-band-c\" id=\"npk05-ct-c\"><\/span>\n <span class=\"mr-band mr-band-w\" id=\"npk05-ct-w\"><\/span>\n <span class=\"mr-band mr-band-s\" id=\"npk05-ct-s\"><\/span>\n <\/div>\n <button class=\"mr-retry\" id=\"npk05-retry\">↻ New Round<\/button>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n<script>\n(function () {\n 'use strict';\n\n var NS = 'npk05';\n var TOTAL = 5;\n var MAX = 20;\n var LTRS = ['A','B','C','D'];\n\n var QS = [\n\n {\n id: 1,\n tag: 'Therapeutic Index — Formula & Calculation',\n stem: 'In an animal study, a drug produces the desired effect in 50% of animals at a dose of <strong>20 mg\/kg<\/strong>, and causes death in 50% of animals at a dose of <strong>200 mg\/kg<\/strong>. What is the <strong>therapeutic index<\/strong> of this drug, and how should it be interpreted?',\n correct: 'TI = 10; the drug has a relatively wide safety margin with a tenfold difference between the effective and lethal doses',\n opts: [\n 'TI = 10; the drug has a relatively wide safety margin with a tenfold difference between the effective and lethal doses',\n 'TI = 0.1; the drug is dangerous because the lethal dose is only a fraction of the effective dose',\n 'TI = 10; the drug has a narrow safety margin and requires therapeutic drug monitoring',\n 'TI = 180; calculated as the difference between LD50 and ED50, representing the absolute safe dose range'\n ],\n exp: 'The formula \u2014 and the direction of division matter:<span class=\"calc\">Therapeutic Index (TI) = LD50 ÷ ED50<br>= 200 mg\/kg ÷ 20 mg\/kg = <strong>10<\/strong><\/span>Interpretation: a TI of 10 means the lethal dose is <strong>10 times<\/strong> the effective dose. This is actually a <em>reasonable<\/em> safety margin \u2014 not narrow. Trap C gives the right number but the wrong interpretation. Trap B inverts the formula (ED50 ÷ LD50), giving 0.1. Trap D subtracts instead of divides \u2014 a common arithmetic error. <br><br>Reference anchors for TI:<br>• <strong>TI > 10<\/strong> \u2192 relatively safe (e.g. penicillin, TI > 100)<br>• <strong>TI < 2<\/strong> \u2192 narrow therapeutic index; requires monitoring<br>• Classic NTI drugs: <strong>digoxin, lithium, phenytoin, warfarin, theophylline, aminoglycosides<\/strong>'\n },\n\n {\n id: 2,\n tag: 'Therapeutic Index — Narrow vs Wide, Clinical Consequences',\n stem: 'Drug A has a therapeutic index of <strong>1.5<\/strong>. Drug B has a therapeutic index of <strong>100<\/strong>. A patient on Drug A develops mild renal impairment causing a <strong>30% reduction in drug clearance<\/strong>. Which statement best describes the clinical consequence?',\n correct: 'Drug A becomes immediately dangerous; a 30% rise in plasma concentration in a drug with TI of 1.5 is likely to push the patient into the toxic range',\n opts: [\n 'Drug A becomes immediately dangerous; a 30% rise in plasma concentration in a drug with TI of 1.5 is likely to push the patient into the toxic range',\n 'Drug B is more dangerous because it has a higher absolute plasma concentration at therapeutic doses',\n 'Both drugs are equally affected; a 30% reduction in clearance raises plasma concentration by 30% regardless of TI',\n 'Drug A is safer because its low TI means the body tolerates a wider range of plasma concentrations before toxic effects appear'\n ],\n exp: 'Reduced clearance \u2192 reduced elimination \u2192 drug accumulates \u2192 plasma concentration rises ~30%.<br><br>Now apply TI:<span class=\"calc\">Drug A: TI = 1.5<br>Toxic dose = only 1.5\u00d7 the effective dose<br>A 30% rise in concentration crosses into toxic territory immediately.<br><br>Drug B: TI = 100<br>Toxic dose = 100\u00d7 the effective dose<br>A 30% rise is clinically trivial — still far from toxicity.<\/span>This is the <em>clinical meaning<\/em> of TI: it defines how much room you have. Drug A with TI 1.5 has almost none. Trap C is arithmetically true but clinically meaningless without TI context. Trap D inverts the logic completely — a low TI means <strong>less<\/strong> tolerance, not more. NTI drugs (digoxin, lithium, warfarin) need monitoring precisely because small clearance changes tip patients into toxicity.'\n },\n\n {\n id: 3,\n tag: 'ED50 — Dose-Response Curve Reading',\n stem: 'Two drugs, X and Y, both treat the same condition. Drug X produces 50% of maximal effect at <strong>5 mg<\/strong>. Drug Y produces 50% of maximal effect at <strong>50 mg<\/strong>. The maximal effect of both drugs is identical. Which statement is correct?',\n correct: 'Drug X is more potent than Drug Y; it achieves the same submaximal effect at a tenfold lower dose, though potency says nothing about the maximum effect either drug can produce',\n opts: [\n 'Drug X is more potent than Drug Y; it achieves the same submaximal effect at a tenfold lower dose, though potency says nothing about the maximum effect either drug can produce',\n 'Drug X is more efficacious than Drug Y because it requires a lower dose to produce its effect',\n 'Drug Y is safer than Drug X because its higher ED50 means toxic effects occur at proportionally higher doses',\n 'Drug X and Drug Y have identical clinical utility since their maximal effects are the same; ED50 is irrelevant when efficacy is equal'\n ],\n exp: '<strong>Potency vs Efficacy<\/strong> \u2014 the distinction examiners love:<br><br>• <strong>Potency<\/strong>: the dose required to produce a given effect. Lower ED50 = more potent. Drug X (ED50 = 5 mg) is <strong>10\u00d7 more potent<\/strong> than Drug Y (ED50 = 50 mg).<br>• <strong>Efficacy<\/strong>: the <em>maximum<\/em> effect a drug can produce. Both drugs have identical maximum effect \u2192 <strong>equal efficacy<\/strong>.<span class=\"calc\">Potency ratio = ED50(Y) ÷ ED50(X) = 50 ÷ 5 = <strong>10<\/strong><br>Drug X is 10\u00d7 more potent.<\/span>Trap B conflates potency with efficacy \u2014 a lower dose requirement does not mean a greater maximum effect. Trap C is wrong: ED50 says nothing about the toxic dose (that is LD50 or TD50). Trap D is wrong: potency matters clinically for dosing convenience and side-effect profile even when maximal efficacy is equal. Morphine and codeine have the same ceiling, but morphine\\'s higher potency makes it the choice for severe pain.'\n },\n\n {\n id: 4,\n tag: 'Certain Safety Factor — TD50 vs LD50',\n stem: 'In human pharmacology, the <strong>Certain Safety Factor (CSF)<\/strong> is preferred over the classic therapeutic index for assessing drug safety. Given: ED99 = <strong>40 mg\/kg<\/strong> and TD1 = <strong>80 mg\/kg<\/strong>. What is the CSF, and what does it tell you?',\n correct: 'CSF = 2; this means the dose causing toxicity in the most sensitive 1% of the population is only twice the dose needed to treat the most resistant 1% of patients \u2014 a dangerously narrow margin',\n opts: [\n 'CSF = 2; this means the dose causing toxicity in the most sensitive 1% of the population is only twice the dose needed to treat the most resistant 1% of patients \u2014 a dangerously narrow margin',\n 'CSF = 2; this is a comfortable safety margin since the toxic dose always exceeds the effective dose in clinical use',\n 'CSF = 0.5; calculated as ED99 ÷ TD1, indicating the effective dose exceeds the toxic dose and the drug should not be used',\n 'CSF = 40; calculated as the absolute difference between TD1 and ED99, representing milligrams of available safety window'\n ],\n exp: 'Formula:<span class=\"calc\">CSF = TD1 ÷ ED99<br>= 80 mg\/kg ÷ 40 mg\/kg = <strong>2<\/strong><\/span>Why CSF is more informative than TI:<br><br>Classic TI uses <strong>median values<\/strong> (LD50\/ED50) \u2014 middle of the population. But populations have outliers. CSF asks a harder question: what happens when you give the dose needed to treat the <em>hardest-to-treat<\/em> patient (ED99) to someone who is the <em>most sensitive to toxicity<\/em> (TD1)?<br><br>A CSF of 2 means these two curves nearly overlap. In a real population, some patients will be harmed while being treated at doses needed to treat others. CSF < 1 means the curves cross \u2014 you cannot treat all patients without harming some. Classic NTI examples: digoxin CSF is close to 1. Trap B mistakes \"CSF >1\" for \"safe\" \u2014 that is only valid when CSF is substantially >1. Trap C inverts the formula.'\n },\n\n {\n id: 5,\n tag: 'TI — Comparing Two Drugs Clinically',\n stem: 'A new sedative (Drug N) and an established sedative (Drug E) are compared in animal studies:<br><br><strong>Drug N:<\/strong> ED50 = 10 mg\/kg | LD50 = 15 mg\/kg<br><strong>Drug E:<\/strong> ED50 = 50 mg\/kg | LD50 = 500 mg\/kg<br><br>Which drug would you prefer for clinical use, and why?',\n correct: 'Drug E; its TI of 10 is far safer than Drug N\\'s TI of 1.5, despite Drug N appearing more potent',\n opts: [\n 'Drug E; its TI of 10 is far safer than Drug N\\'s TI of 1.5, despite Drug N appearing more potent',\n 'Drug N; its lower ED50 means it is more potent and therefore requires smaller, safer doses in clinical practice',\n 'Drug N; since both LD50 values are above the ED50, both drugs are equally safe and the choice should be based on cost',\n 'Drug E; its higher ED50 means patients are less likely to accidentally take an effective dose, reducing the risk of overdose'\n ],\n exp: 'Calculate TI for both:<span class=\"calc\">Drug N: TI = LD50 ÷ ED50 = 15 ÷ 10 = <strong>1.5<\/strong><br>Drug E: TI = LD50 ÷ ED50 = 500 ÷ 50 = <strong>10<\/strong><\/span>Drug N is more <em>potent<\/em> (lower ED50) but dramatically less <em>safe<\/em>. A TI of 1.5 means the lethal dose is only 50% above the effective dose \u2014 an almost nonexistent margin. Any dosing error, pharmacokinetic variability, or drug interaction could prove fatal.<br><br>Drug E with TI = 10 has a tenfold buffer. This is the core lesson of TI: <strong>potency and safety are independent axes<\/strong>. The most potent drug is not the best drug. Botulinum toxin is the most potent substance known \u2014 its ED is vanishingly small, but so is its margin to lethality. Trap B is the classic error of equating potency with safety. Trap D is creative but pharmacologically backwards \u2014 a high ED50 is not a safety feature, it just means you need more drug.'\n }\n\n ];\n\n var answers = {}, answered = 0, shuffled = {}, done = false;\n\n function gid(s) { return document.getElementById(NS + '-' + s); }\n function byId(s) { return document.getElementById(s); }\n\n function shuffleArr(arr) {\n var a = arr.slice(), i, j, t;\n for (i = a.length - 1; i > 0; i--) {\n j = Math.floor(Math.random() * (i + 1));\n t = a[i]; a[i] = a[j]; a[j] = t;\n }\n return a;\n }\n\n function countVal(v) {\n var n = 0, k;\n for (k in answers) { if (answers[k] === v) n++; }\n return n;\n }\n\n function buildPips() {\n var cont = gid('pips'), i, q, wLine, wPip, line, pip;\n cont.innerHTML = '';\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n if (i > 0) {\n wLine = document.createElement('div');\n wLine.className = 'mr-pip-wrap';\n line = document.createElement('div');\n line.className = 'mr-pip-line';\n line.id = NS + '-pl' + q.id;\n wLine.appendChild(line);\n cont.appendChild(wLine);\n }\n wPip = document.createElement('div');\n wPip.className = 'mr-pip-wrap';\n pip = document.createElement('div');\n pip.className = 'mr-pip';\n pip.id = NS + '-pip' + q.id;\n pip.textContent = String(q.id);\n wPip.appendChild(pip);\n cont.appendChild(wPip);\n }\n }\n\n function build() {\n var cont, i, q, opts, card, top, numDiv, meta, tag, stem,\n rule, optsDiv, expDiv, lbl, txt, j, optEl, ltrSpan, txtSpan;\n\n cont = gid('cases');\n cont.innerHTML = '';\n answers = {}; answered = 0; shuffled = {}; done = false;\n gid('score').style.display = 'none';\n buildPips();\n\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n opts = shuffleArr(q.opts);\n shuffled[q.id] = opts;\n\n card = document.createElement('div');\n card.className = 'mr-case';\n\n top = document.createElement('div');\n top.className = 'mr-case-top';\n\n numDiv = document.createElement('div');\n numDiv.className = 'mr-num';\n numDiv.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n\n meta = document.createElement('div');\n meta.className = 'mr-meta';\n\n tag = document.createElement('div');\n tag.className = 'mr-tag';\n tag.innerHTML = q.tag;\n\n stem = document.createElement('div');\n stem.className = 'mr-stem';\n stem.innerHTML = q.stem;\n\n meta.appendChild(tag);\n meta.appendChild(stem);\n top.appendChild(numDiv);\n top.appendChild(meta);\n card.appendChild(top);\n\n rule = document.createElement('div');\n rule.className = 'mr-rule';\n card.appendChild(rule);\n\n optsDiv = document.createElement('div');\n optsDiv.className = 'mr-opts';\n\n for (j = 0; j < opts.length; j++) {\n optEl = document.createElement('div');\n optEl.className = 'mr-opt';\n optEl.id = NS + '-o' + q.id + '-' + j;\n optEl.setAttribute('role', 'button');\n optEl.setAttribute('tabindex', '0');\n\n ltrSpan = document.createElement('span');\n ltrSpan.className = 'mr-ltr';\n ltrSpan.textContent = LTRS[j];\n\n txtSpan = document.createElement('span');\n txtSpan.className = 'mr-opt-text';\n txtSpan.innerHTML = opts[j];\n\n optEl.appendChild(ltrSpan);\n optEl.appendChild(txtSpan);\n optsDiv.appendChild(optEl);\n\n (function (qid, oi) {\n optEl.addEventListener('click', function () { pick(qid, oi); });\n }(q.id, j));\n }\n card.appendChild(optsDiv);\n\n expDiv = document.createElement('div');\n expDiv.className = 'mr-exp';\n expDiv.id = NS + '-exp' + q.id;\n\n lbl = document.createElement('div');\n lbl.className = 'mr-exp-lbl';\n lbl.textContent = 'Debrief';\n\n txt = document.createElement('div');\n txt.className = 'mr-exp-text';\n txt.innerHTML = q.exp;\n\n expDiv.appendChild(lbl);\n expDiv.appendChild(txt);\n card.appendChild(expDiv);\n cont.appendChild(card);\n }\n }\n\n function pick(qid, oi) {\n var q, opts, i, el, correct;\n if (answers[qid] !== undefined || done) return;\n\n q = null;\n for (i = 0; i < QS.length; i++) {\n if (QS[i].id === qid) { q = QS[i]; break; }\n }\n if (!q) return;\n\n opts = shuffled[qid];\n correct = (opts[oi] === q.correct);\n answers[qid] = correct ? 'c' : 'w';\n answered++;\n\n for (i = 0; i < opts.length; i++) {\n el = byId(NS + '-o' + qid + '-' + i);\n if (opts[i] === q.correct) {\n el.className = 'mr-opt correct locked';\n } else if (i === oi) {\n el.className = 'mr-opt wrong locked';\n } else {\n el.className = 'mr-opt dimmed locked';\n }\n }\n\n byId(NS + '-exp' + qid).style.display = 'block';\n byId(NS + '-pip' + qid).className = 'mr-pip ' + (correct ? 'correct' : 'wrong');\n\n if (qid > 1) {\n var pl = byId(NS + '-pl' + qid);\n if (pl) { pl.className = 'mr-pip-line done'; }\n }\n }\n\n function showScore() {\n var c, w, s, net, pct, disp, verdicts, vi, sc;\n if (done) return;\n done = true;\n\n c = countVal('c');\n w = countVal('w');\n s = TOTAL - answered;\n net = (c * 4) - w;\n pct = Math.max(0, Math.round((net \/ MAX) * 100));\n disp = Math.min(100, Math.max(0, pct));\n\n gid('ring').style.background =\n 'conic-gradient(#1A5F7A ' + disp + '%, #B8D8E3 0%)';\n\n gid('pct').textContent = pct + '%';\n gid('net').textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n\n verdicts = [\n [5, 'Perfect. TI formula, CSF, potency vs efficacy \\u2014 all sharp. These are free marks in the exam.'],\n [4, 'Strong round. One concept to consolidate \\u2014 check the debrief and move on.'],\n [3, 'Good base. The CSF question and potency\\u2013efficacy distinction are where the gaps are \\u2014 re-read those two debriefs.'],\n [2, 'The TI formula is the foundation. Own it cold: LD50 \\u00f7 ED50, higher is safer. Everything else builds from there.'],\n [0, 'Start with Q1 and Q5 \\u2014 both are pure calculation. Once the formula is locked in, the conceptual questions become readable.']\n ];\n gid('verdict').textContent = verdicts[4][1];\n for (vi = 0; vi < verdicts.length; vi++) {\n if (c >= verdicts[vi][0]) {\n gid('verdict').innerHTML = verdicts[vi][1];\n break;\n }\n }\n\n gid('ct-c').textContent = '\\u2705 ' + c + ' Correct';\n gid('ct-w').textContent = '\\u274C ' + w + ' Wrong';\n gid('ct-s').textContent = '\\u23ED ' + s + ' Skipped';\n\n sc = gid('score');\n sc.style.display = 'block';\n sc.scrollIntoView({ behavior: 'smooth', block: 'center' });\n }\n\n function tryInit() {\n var sentinel = document.getElementById(NS + '-sentinel');\n var submit = document.getElementById(NS + '-submit');\n var retry = document.getElementById(NS + '-retry');\n if (!sentinel || !submit || !retry) {\n setTimeout(tryInit, 80);\n return;\n }\n submit.addEventListener('click', showScore);\n retry.addEventListener('click', function () {\n build();\n window.scrollTo(0, 0);\n });\n var bar = document.getElementById(NS + '-progress');\n if (bar && window.IntersectionObserver) {\n new IntersectionObserver(function (entries) {\n bar.className = entries[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n }, { threshold: 0 }).observe(sentinel);\n }\n build();\n }\n\n tryInit();\n\n}());\n<\/script>\n\n<\/html>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05 Numerical Series · Pharmacokinetics Morning Rounds · Round 05 of 07 Therapeutic Index,ED50 & LD50 Five questions · Safety margins, dose-response curves & the drugs that live on the edge 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻… <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,79],"tags":[83],"class_list":["post-37349","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-pharmacology","tag-neet-pg"],"yoast_head":"\n<title>Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05 Numerical Series · Pharmacokinetics Morning Rounds · Round 05 of 07 Therapeutic Index,ED50 & LD50 Five questions · Safety margins, dose-response curves & the drugs that live on the edge 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻… \" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-23T05:01:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-23T05:01:59+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Pharmacokinetics – Therapeutic Index, ED50 & LD50\",\"datePublished\":\"2026-08-23T05:01:14+00:00\",\"dateModified\":\"2026-08-23T05:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\"},\"wordCount\":55,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"keywords\":[\"NEET-PG\"],\"articleSection\":[\"Morning Rounds\",\"Pharmacology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\",\"name\":\"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-08-23T05:01:14+00:00\",\"dateModified\":\"2026-08-23T05:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-therapeutic-index-ed50-ld50\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacokinetics – Therapeutic Index, ED50 & LD50\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n","yoast_head_json":{"title":"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","og_locale":"en_US","og_type":"article","og_title":"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty","og_description":"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 05 Numerical Series · Pharmacokinetics Morning Rounds · Round 05 of 07 Therapeutic Index,ED50 & LD50 Five questions · Safety margins, dose-response curves & the drugs that live on the edge 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻… ","og_url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","og_site_name":"atsixty","article_published_time":"2026-08-23T05:01:14+00:00","article_modified_time":"2026-08-23T05:01:59+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Pharmacokinetics – Therapeutic Index, ED50 & LD50","datePublished":"2026-08-23T05:01:14+00:00","dateModified":"2026-08-23T05:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/"},"wordCount":55,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"keywords":["NEET-PG"],"articleSection":["Morning Rounds","Pharmacology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/","name":"Pharmacokinetics - Therapeutic Index, ED50 & LD50 - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-08-23T05:01:14+00:00","dateModified":"2026-08-23T05:01:59+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-therapeutic-index-ed50-ld50\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Pharmacokinetics – Therapeutic Index, ED50 & LD50"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37349"}],"version-history":[{"count":2,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37349\/revisions"}],"predecessor-version":[{"id":37351,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37349\/revisions\/37351"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}